Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333482 · ClinicalTrials.gov registry record · NA
Flourish: Exploring the Early Infant Gut Microbiome
A NA study of Eczema and Gut Microbiome, sponsored by Seeding.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT07333482: Recruiting NA study of Eczema and Gut Microbiome, sponsored by Seeding.
NCT07333482 is a NA study of Eczema and Gut Microbiome that is actively recruiting participants, run by Seeding. The registered enrollment target is 250 participants, above the 198-participant average among 29 other Eczema trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07333482, a NA study of Eczema and Gut Microbiome, is actively recruiting participants, sponsored by Seeding.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.
Primary Outcome
Changes in gut microbiota composition, including relative abundance of beneficial bacterial taxa such as Bifidobacterium, assessed using shotgun metagenomic sequencing.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Tailored Recommendations
- BEHAVIORAL Consult Call
- BEHAVIORAL Educational Email Series
Study Locations (1)
Texas
- Seeding Labs INC - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2028-09 |
| Phase | NA |
What NCT07333482 shows while recruiting
NCT07333482 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 198-participant average among 29 other Eczema trials with a reported enrollment target (26% higher).
The record links to 4 conditions, with Eczema appearing as the primary indexed condition, and to 3 interventions - of which Tailored Recommendations is the first listed.
NCT07333482 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07333482 about?
NCT07333482 is a clinical study titled "Flourish: Exploring the Early Infant Gut Microbiome". The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these inter...
What is the current status of trial NCT07333482?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2026-01-31. Estimated completion is 2028-09.
What conditions does trial NCT07333482 study?
This clinical trial studies the following conditions: Eczema, Gut Microbiome, Microbiome, Microbiota.
What interventions are being tested in trial NCT07333482?
The interventions under investigation include: Tailored Recommendations (DIETARY_SUPPLEMENT), Consult Call (BEHAVIORAL), Educational Email Series (BEHAVIORAL).
Who is sponsoring clinical trial NCT07333482?
This trial is sponsored by Seeding, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07333482 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07333482's enrollment target sits among peer trials
250 8th of 29 higher than 22 of 29 other Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infant Restore: Efficacy of Microbiome Analysis and Education
ACTIVE NOT RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
COMPLETED · NA
-
Joovvin' for Your Skin Health Study
COMPLETED · NA
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI